Jupiter Neurosciences, Inc.
JUNS
$0.34
-$0.01-3.29%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -76.17% | 788.68% | 651.14% | 372.85% | -17.86% |
| Gross Profit | 87.01% | -788.68% | -651.14% | -372.85% | 17.86% |
| SG&A Expenses | 121.31% | 268.63% | 230.13% | 126.97% | 332.24% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 94.09% | 365.47% | 306.55% | 169.49% | 172.29% |
| Operating Income | -92.59% | -365.47% | -306.55% | -169.49% | -172.29% |
| Income Before Tax | -68.57% | -287.14% | -819.58% | -141.11% | -255.59% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -68.57% | -287.14% | -819.58% | -141.11% | -255.59% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -68.57% | -287.14% | -819.58% | -141.11% | -255.59% |
| EBIT | -92.59% | -365.47% | -306.55% | -169.49% | -172.29% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -39.54% | -253.68% | -695.61% | -93.31% | -196.32% |
| Normalized Basic EPS | -65.37% | -252.94% | -192.41% | -81.76% | -177.45% |
| EPS Diluted | -40.37% | -253.68% | -800.00% | -93.31% | -141.50% |
| Normalized Diluted EPS | -65.37% | -252.94% | -226.15% | -81.76% | -177.45% |
| Average Basic Shares Outstanding | 20.66% | 9.57% | 20.50% | 24.80% | 19.71% |
| Average Diluted Shares Outstanding | 20.66% | 9.57% | 8.46% | 24.80% | 19.71% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |